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Objective: To investigate the early detection of the damage of cochlear activity by using
distortion product otoacoustic emissions (DPOAE) (DP-gram) comparing to the results of
the impedance audiometry.
Methods: We examined 53 patients including 43 hemodialyzed patients, and 10 con-
trols. First it was applied a tympanometry, and then in normal results we applied
impedance audiometry and DPOAE (DP-gram).
Results: We found sensorineural hearing loss in 67% of audiometric results of the
hemodialyzed patients and there was a decrease of the DPOAE amplitude in 77% of
hemodialyzed patients. In the control group there was one patient (10%) with neuro-
sensorial in high frequencies hearing loss in both measurements with audiometry and
DPOAE.
Conclusions: There is a sensorineural hearing loss observed in most of the patients with
chronic renal failure. DPOAE audiogram shows lower amplitudes than impedance
audiometry and it can be used for the early detection of cochlear damage.1. Introduction
Otoacoustic emissions are tests used to determine the hair cell
function of the cochlea. Sootoacoustic emission testing can be used
as a tool to determine the presence or absence of cochlear function
and analysis can be performed for individual cochlear frequency
regions[1,2]. Another potential use of distortion product otoacoustic
emissions (DPOAE) measurements might be to predict auditory
response growth, such as growth of loudness. This application
would be of interest clinically because one consequence of
cochlear hearing loss may be an abnormal growth of loudness,
sometimes referred to as loudness recruitment[3].
DPOAEs are sounds emitted in response to 2 simultaneous
tones of different frequencies. Stimuli consist of 2 pure tones at
2 frequencies (f2 > f1) and two intensity levels (L1, L2)[4,5]. The
relationship between L1–L2 and f1/f2 dictates the frequency
response. DPOAEs allow great frequency speciﬁcity with a
great reliability above 1000 Hz[6].
Hearing losses above 50 dB HL are not quantiﬁable using
DPOAEs and their performance at frequencies below 1 kHz is
limited, but their recording time is short[7].Presence of hearing loss and estimation of type and degree is
one of themost commonmethods used to investigate the effects of
renal disease on the auditory system[8]. Degree of hearing lossmay
give an indication of the extent of damage to auditory function,
whereas the type of hearing loss may distinguish between
lesions in the outer and middle ear (conductive hearing loss) or
the cochlea and the neural pathways (sensorineural hearing
loss)[9]. According to these indicators, the reports to be reviewed
in the following sections have also described auditory function
in CRF with methods such as tympanometry, audiometry and
otoacoustic emissions (distortion product OAEs, DPOAEs).
2. Materials and methods
We analyzed 53 patients (106 ears) including 43 subjects of
different stages of renal failure disease undergoing hemodialysis
treatment and 10 controls.
The criteria for case selection were: age 15–50 years[10],
hearing impairment after the occurrence of renal failure, no
history of noise exposure, no history of diabetes, no history of
renal transplantation.
The criteria for healthy volunteers were: age 15–50 years,
normal renal function tests, no history of noise exposure, no
history of diabetes, no history of renal transplantation.
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and serum creatinine and associated oliguria. We did hearing
evaluation by using tympanometry, impedance audiometry and
DPOAE. We used a setting of 65/55 dB SPL L1/L2 in DPOAE
examination.
3. Results
According to the results of the examinations done to the
patients it showed that 29 patients out of 43 under hemodialysisFigure 1. DPOAE ﬁndings in CRF patients.
Figure 2. DPOAE and audiometric results of one of our patients.treatment had sensorineural hearing loss in high frequencies in
audiometric measurements and 33 of them had decreased
DPOAE amplitudes (Figure 1).
In the control group only one patient had pure tone audi-
ometry (PTA) threshold low in high frequencies and DPOAE
gram according to the audiogram but lower values in >4000 Hz.
It was observed a higher incidence of hearing loss in stages
three, four and ﬁve of renal failure with lower amplitudes in the
DP-gram than PTA thresholds in the same frequencies
(Figures 2 and 3).
Figure 3. DPOAE and audiometric results, second patient.
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The survival of chronic renal failure patients is increased with
the new hemodialysis treatments[11].
The impact of hearing loss on these patients in the social
integration has to be addressed. So both primary prevention and
early detection of hearing loss are important for providing
management options.
As screening tools, DPOAEs are superior to PTA testing.
DPOAE amplitude reduces signiﬁcantly before behavioral
threshold changes are noted at corresponding frequencies in
PTA. Decreased emissions in the presence of normal behavioral
hearing may indicate an underlying pathologic condition, which
if continued might soon result in a signiﬁcant hearing loss[12]. In
this sense, the DP-grams may be predictive, foretelling a sub-
stantial threshold shift for a given frequency before a measurable
sensitivity loss[13].
Our study demonstrated that DP-grams seem to be a more
sensitive test than PTA for determining cochlear dysfunction.
DPOAEs have an extensive dynamic range regarding hearing
loss and can be measured over a broader frequency range with
more sensitive frequency speciﬁc response[14]. With their high
sensitivity and excellent reliability, their objectivity makes
them ideal for testing patients who cannot cooperate in a
traditional examination of behavioral hearing. Their recording
is easy for both technician and patient, and can be easily
performed at the bedside. DPOAE audiograms provide a tool
for a fast automated frequency-speciﬁc and quantitative evalu-
ation of a mild or moderate hearing in follow-up diagnosis[15].
Therefore after a complete audiometric valuation it has to be
established to monitor these patients periodically using DP-
grams alone causing less inconvenience to these patients who
are not feeling well.Conﬂict of interest statement
The authors report no conﬂict of interest.
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